MYC inhibitor

DRUG CLASS:

MYC inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
KRAS G12A	Chronic Myeloid Leukemia	KRAS G12A	Chronic Myeloid Leukemia	GT19077 Sensitive: C3 – Early Trials GT19077 Sensitive : C3	GT19077 Sensitive: C3 – Early Trials GT19077 Sensitive : C3
MAF overexpression	Multiple Myeloma	MAF overexpression	Multiple Myeloma	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
MRC1 expression	Small Cell Lung Cancer	MRC1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3
MYC translocation	Acute Myelogenous Leukemia	MYC translocation	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Acute Myelogenous Leukemia	IGH translocation	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC translocation	Multiple Myeloma	MYC translocation	Multiple Myeloma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Multiple Myeloma	IGH translocation	Multiple Myeloma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC translocation	Lymphoma	MYC translocation	Lymphoma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Lymphoma	IGH translocation	Lymphoma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Lymphoma	KRAS G12A	Lymphoma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Multiple Myeloma	KRAS G12A	Multiple Myeloma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Acute Myelogenous Leukemia	KRAS G12A	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC-IGH fusion	Chronic Lymphocytic Leukemia	MYC-IGH fusion	Chronic Lymphocytic Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Chronic Lymphocytic Leukemia	KRAS G12A	Chronic Lymphocytic Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC-IGH fusion	Chronic Myeloid Leukemia	MYC-IGH fusion	Chronic Myeloid Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC-IGH fusion	Acute Myelogenous Leukemia	MYC-IGH fusion	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + PLX51107 Sensitive: D – Preclinical quizartinib + PLX51107 Sensitive : D	quizartinib + PLX51107 Sensitive: D – Preclinical quizartinib + PLX51107 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	PLX51107 Sensitive: D – Preclinical PLX51107 Sensitive : D	PLX51107 Sensitive: D – Preclinical PLX51107 Sensitive : D
IDH2 mutation	Glioma	IDH2 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
MYC overexpression	Gastric Cancer	MYC overexpression	Gastric Cancer	WB100 Sensitive: D – Preclinical WB100 Sensitive : D	WB100 Sensitive: D – Preclinical WB100 Sensitive : D
MYC overexpression	Pancreatic Ductal Adenocarcinoma	MYC overexpression	Pancreatic Ductal Adenocarcinoma	WB100 Sensitive: D – Preclinical WB100 Sensitive : D	WB100 Sensitive: D – Preclinical WB100 Sensitive : D
MYC overexpression	Acute Myelogenous Leukemia	MYC overexpression	Acute Myelogenous Leukemia	WB100 Sensitive: D – Preclinical WB100 Sensitive : D	WB100 Sensitive: D – Preclinical WB100 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	MYCi975 Sensitive: D – Preclinical MYCi975 Sensitive : D	MYCi975 Sensitive: D – Preclinical MYCi975 Sensitive : D
MYC overexpression	Triple Negative Breast Cancer	MYC overexpression	Triple Negative Breast Cancer	PD-L1 inhibitor + MYC inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + MYC inhibitor Sensitive : D	PD-L1 inhibitor + MYC inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + MYC inhibitor Sensitive : D
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	OMO-103 Sensitive: D – Preclinical OMO-103 Sensitive : D	OMO-103 Sensitive: D – Preclinical OMO-103 Sensitive : D
MYC overexpression	Small Cell Lung Cancer	MYC overexpression	Small Cell Lung Cancer	ICX-101 Sensitive: D – Preclinical ICX-101 Sensitive : D	ICX-101 Sensitive: D – Preclinical ICX-101 Sensitive : D

MYC inhibitor

MYC inhibitor

Associations(30)

Associations
(30)